Children experiencing seizures related to KCNQ2-DEE may be eligible for the EPIK Study

About the Study

Our team of medical professionals is evaluating an investigational medication to determine if it may reduce the number of seizures experienced by children diagnosed with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).

If your child is eligible to participate, the study includes:

- Screening followed by 2 to 4 weeks to collect initial information
- Up to 15 weeks of treatment
- After treatment, up to 18 days to reduce medication dosage
- Approximately 4 weeks of follow up

Your child's participation may range from 17 weeks to 28 weeks in total duration. Participation will include visits to the doctor's office. For some of the scheduled visits, you will also have the option for home health appointments where a study nurse will visit your home.

The study medication will be packaged in capsules. Each capsule should be opened and contents mixed with your child's soft foods or drinks, three times a day. Your child's dosage will be based on your child's weight, and may be adjusted throughout the study as needed.

Consider Participating in the EPIK Study

Clinical investigations such as these play an important role in discovering potential new treatment options. By choosing to participate in the EPIK Study, you are helping to advance scientific knowledge of a treatment approach for children experiencing seizures due to a mutation in the KCNQ2 gene.

Your decision to have your child participate, or not participate, in this study will in no way affect the medical care that they receive now or in the future. As with all clinical research, participation is voluntary, you may discontinue at any time, and there are risks and potential benefits involved.

To learn more or to schedule a Screening Visit, please speak with a member of the study team.

[SPACE FOR SITE CONTACT INFO]

EPIK

Xenon_EPIK_XPF-009-301_US English_Patient Brochure_v2.0_24NOV2020



A Study is Enrolling Children with KCNQ2 Developmental and Epileptic Encephalopathy

A clinical trial is looking at how effective and safe a new precision medication is to treat children with KCNQ2-DEE

EPIK

About KCNQ2

KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) is a condition that causes seizures during infancy due to a mutation in the KCNQ2 gene. Seizures can begin as early as the first day of life.

Seizures with KCNQ2-DEE may be frequent, severe, and difficult to control. Further, a child's motor, social, language, and cognition skills may be impacted by the disease. Many children also exhibit features such as repetitive movements, poor eye contact, self-harm and sensitivity to sound.

Diagnosing KCNQ2-DEE

When children experience seizures, various tests must first be performed to determine the possible causes of seizures. One way of evaluating cause is with an electroencephalogram (EEG). An EEG is a non-invasive test that records electrical patterns in the brain. Magnetic resonance imaging (MRI) is another non-invasive technique used that produces detailed images of soft tissue. However, diagnosis of KCNQ2-DEE requires molecular genetic testing (gene tests) to look for mutations in a patient's genes.

About Clinical Trials

What is a clinical research study?
A clinical research study is a study performed in people to advance medical knowledge in a carefully supervised research setting. These can include testing an investigational medication before it is made available to the public. Clinical research studies are performed according to government regulations that help protect the safety and rights of study participants. Participation in a clinical research study is completely voluntary. Before a study volunteer enters a study, a study doctor will discuss the details of the study. These details include information about the investigational study medication, what happens during the study, and any potential risks or side effects.

A research program is undertaken by doctors and scientists to:

- Answer specific health questions
- Evaluate the safety and effectiveness of investigational medications or devices
- Discover new ways to improve health

Why Should My Child Participate?

If your child is eligible and you choose to participate, you will receive at no cost:

- All study-related medication
- Close care and monitoring from our team of medical professionals
- An electronic diary to track the frequency and severity of your child's seizures for the duration of the study
- Travel arrangements and payment/ reimbursement for study-related travel expenses

Would My Child Be Considered for the Study?

To be considered, participants must:

- Be between the ages of 1 month up to 6 years of age
- Experience seizures starting within the first 2 weeks after birth
- Experience 4 or more seizures a month
- Be taking at least 1, and up to 4, anti-seizure medications

For more information and to see if your child qualifies, visit **www.EPIKstudy.com** or call the doctor's office listed on the back of this brochure.

EPIK